Patrick Gould, Devyn Coskey, Xin Ma, Shikun Wang, Sonia Godbole, David Bond, Andrew Ip, Snegha Ananth, Shaunak Varma, Emily Ayers, Rachel Faden, Cassandra Gillespie, Basem William, Ryan Jacobs, Bei Hu, Jake Lattin, David Russler-Germain, Michele Stanchina, Ashley Rose, Michael Randall, Michael Spinner, Vidiya Srikakulapu, Praveen Ramakrishnan Geethakumari, Alan Skarbnik, David W Chitty, Mazie Tsang, Cassandra Duarte, Ajay Major, Allison M Bock, Kelsey Baron, Brian Hess, Seda Tolu, Barbara Pro, Supriya Vaidya, Jennifer E Amengual, Ran Reshef, Hua-Jay J Cherng
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a non-invasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We conducted a multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM). Our primary objective was to assess post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy. Median time from sample collection to MRD result was 9 days. Following frontline treatment (N=102), 12-month progression-free survival (PFS) was 15% versus 85% for detectable versus undetectable MRD (HR 14.5, p.